CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
June 2016—Eurofins Scientific has acquired PerkinElmer’s U.S. prenatal screening laboratory services business, PerkinElmer Labs/NTD.
“This acquisition reflects our strategy of expanding and strengthening our network of competence centers. NTD strengthens Eurofins’ testing capabilities for genetic disorders, and the group’s footprint in the specialty clinical diagnostics market, with truly unique and innovative services with high positive impact for patient care. In combination with ViraCor and Diatherix for infectious diseases, Boston Heart for cardiovascular, and EGL for genetic diseases, NTD’s expertise in prenatal screening reinforces the group’s position in advanced diagnostic testing to better serve the global health care community,” Gilles Martin, PhD, CEO of Eurofins, said in a statement.
NTD generated revenues of about $20 million in 2015 and employs approximately 80 people at its Melville, NY, laboratory.
Eurofins Scientific, 515-280-8378